Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug (Ursodeoxycholic acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies),

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug (Ursodeoxycholic acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug (Ursodeoxycholic acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Progressive familial intrahepatic cholestasis refers to a collection of rare genetic disorders due to defective mechanisms of bile secretion. Typically divided into three subtypes, PFIC type 1, PFIC type 2, and PFIC type 3. The condition is usually diagnosed in the early years of life and often presents with signs and symptoms of intrahepatic cholestasis, such as pruritis, dark urine, pale stool, loss of appetite, and fatigue. Mutations in the ABCB11 gene are responsible for PFIC2. The ABCB11 gene provides instructions for making a protein called the bile salt export pump (BSEP). The protein is found in the liver, and its main role is to move bile salts (a component of bile) out of liver cells. Mutations in the ABCB11 gene result in the buildup of bile salts in liver cells, damaging these cells and causing liver disease.

Market Dynamics

The key players in the pharmaceutical industry are focusing on the development of new drugs and accessing new mechanisms of action to treat progressive familial intrahepatic cholestasis type 2. Thus, the introduction of such new products into the market is expected to drive growth of the global progressive familial intrahepatic cholestasis type 2 treatment market over the forecast period. For instance, on February 14, 2023, Mirum Pharmaceuticals, Inc., a biopharmaceutical company, announced that the company has submitted a supplemental New Drug Application (sNDA) for LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC). The sNDA submission is based on data from the March PFIC sPhase 3 study of LIVMARLI. MARCH PFIC is the largest randomized trial conducted in PFIC, with 93 patients across a range of genetic PFIC subtypes, including PFIC1, PFIC2, PFIC3, PFIC4, PFIC6 and unidentified mutational status.

Key features of the study:

• This report provides an in-depth analysis of the global progressive familial intrahepatic cholestasis type 2 treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global progressive familial intrahepatic cholestasis type 2 treatments market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Mylan N.V., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Jadeite Medicines Inc., and Ipsen Pharma.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global progressive familial intrahepatic cholestasis type 2 treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive familial intrahepatic cholestasis type 2 treatment market

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Detailed Segmentation:

• By Drug:
• Ursodeoxycholic acid
• Cholestyramine
• Rifampicin
• Late Stage Pipeline Drugs
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
• Company Profiles
• Teva Pharmaceutical Industries Ltd.
• AbbVie, Inc.
• Glenmark Pharmaceuticals Limited
• Par Pharmaceuticals, Inc.
• Mylan Pharmaceuticals, Inc.
• Sanofi S.A.
• Mylan N.V.
• Novartis International AG
• Akorn, Inc.
• Albireo Pharma, Inc.
• Mirum Pharmaceuticals
• Jadeite Medicines Inc.
• Ipsen Pharma